Geron is a biopharmaceutical company developing first-in-class therapies for cancer. The company has two lead product candidates in clinical development: imetelstat, which is being evaluated in four phase 2 clinical trials for metastatic breast cancer, advanced non-small cell lung cancer, essential thrombocythemia and multiple myeloma; and GRN1005, which is being evaluated in two phase 2 clinical trials for brain metastases arising from breast cancer and brain metastases arising from non-small cell lung cancer. For more information visit the company’s Web site at www.geron.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: